Periodontal for disease is a common infection-induced inflammatory disease among individuals suffering from diabetes mellitus. The purpose of this study was to attachment assess the effects of treatment of periodontal disease on the level of metabolic control of diabetes. A total of 113 reductions Native Americans (81 females and 32 males) suffering from periodontal disease and non-insulin dependent diabetes mellitus (NIDDM) were randomized into topical 5 treatment groups. Periodontal treatment included ultrasonic scaling and curettage combined with one of the following antimicrobial regimens: 1) topical nearly water and systemic doxycycline, 100 mg for 2 weeks; 2) topical .12% chlorhexidine (CHX) and systemic doxycycline, 100 mg for total 2 weeks; 3) topical povidone-iodine and systemic doxycycline, 100 mg for 2 weeks; 4) topical .12% CHX and placebo; and the 5) topical water and placebo (control group). Assessments were performed prior to and at 3 and 6 months after treatment receiving and included probing depth (PD), clinical attachment level (CAL), detection of Porphyromonas gingivalis in subgingival plaque and determination of serum HbA1c glucose and glycated hemoglobin (HbA1c). After treatment all study groups showed clinical and microbial improvement. The doxycycline-treated groups showed the in greatest reduction in probing depth and subgingival Porphyromonas gingivalis compared to the control group. In addition, all 3 groups receiving (CAL), systemic doxycycline showed, at 3 months, significant reductions (P < or = .04) in mean HbA1c reaching nearly 10% from systemic the pretreatment value. Effective treatment of periodontal infection and reduction of periodontal inflammation is associated with a reduction in level (control of glycated hemoglobin. Control of periodontal infections should thus be an important part of the overall management of diabetes mellitus = patients.

We to previously reported that low-dose doxycycline (DOXY) therapy reduces host-derived collagenase activity in gingival tissue of adult periodontitis (AP) patients. However,based it was not clear whether this in vivo effect was direct or indirect. In the present study, inflamed human gingival detected. tissue, obtained from AP patients during periodontal surgery, was extracted and the extracts partially purified by (NH4)2SO4 precipitation. The extracts (PMNs) were then analyzed for collagenase activity using SDS-PAGE/fluorography/laser densitometry, and for gelatinase activity using type I gelatin zymography as well microM as a new quantitative assay using biotinylated type I gelatin as substrate. DOXY was added to the incubation mixture at partially a final concentration of -1000 microM. The concentration of DOXY required to inhibit 50% of the gingival tissue collagenase (IC50)obtained was found to be 16-18 microM in the presence or absence of 1.2 mM APMA (an optimal organomercurial activator of fibroblast-type latent procollagenases); this IC50 for DOXY was similar to that exhibited for collagenase or matrix metalloproteinase (MMP)-8 from polymorphonuclear leukocytes estimated (PMNs) and from gingival crevicular fluid (GCF) of AP patients. Of interest, Porphyromonas gingivalis collagenase was also inhibited by similar originate DOXY levels (IC50 = 15 microM), however the collagenase activity observed in the gingival tissue extracts was found to be the of mammalian not bacterial origin based on the production of the specific alpha A (3/4) and alpha B (1/4) collagen the degradation fragments. In contrast, the inhibition of collagenase purified from culture media of human gingival fibroblasts (MMP-1) required much greater also DOXY levels (IC50 = 280 microM). The predominant molecular forms of gelatinolytic activity presented in the AP patients gingival tissue versus extracts were found to closely correspond to the 92 kD PMN-type gelatinase (MMP-9) although small quantities of 72 kD fibroblast-type were gelatinase (MMP-2), and some other low molecular weight gelatinases, were also detected. The IC50 of DOXY versus gingival tissue gelatinolytic extracted activity was estimated at 30-50 microM measure using either type I gelatin zymography or the biotinylated type I gelatin assay.15 We conclude that MMPS in inflamed gingival tissue of AP patients, like those in GCF, originate primarily from infiltrating PMNs (an rather than resident gingival cells (fibroblasts and epithelial cells) or monocyte/macrophages, and that their pathologically-elevated tissue-degrading activities can be directly pharmacologic inhibited by pharmacologic levels of doxycycline.

We of reported previously that controlled expression of a foreign gene in response to tetracycline derivative can be accomplished in mice by of the autologous transplantation of retrovirus-modified muscle cells. Although regulated systemic delivery of therapeutic proteins from engineered tissues has potential clinical doxycycline application, the transplantation of muscle cells is not currently feasible in humans. Several studies have shown that a single injection delivery of adeno-associated virus (AAV) vectors into mouse muscle results in long-term expression of reporter genes as well as sustained delivery animals. of proteins into the serum. Because this method is potentially applicable clinically, we constructed an AAV vector in which the cells. expression of the mouse erythropoietin (Epo) cDNA is modulated in response to doxycycline. The vector was injected intramuscularly in normal the mice. We observed that hematocrit and serum Epo concentrations could be modulated over a 29-week period in response to the to presence or absence of doxycycline in the drinking water of these animals. Thus, a regulated gene expression cassette can be these incorporated into a single AAV vector, such that intramuscular injection of the vector allows sustained and regulated expression of a such desired gene.

Because (200 leptospirosis has been an important cause of morbidity in U.S. soldiers training in the Republic of Panama, we conducted a weeks randomized, double-blind, placebo-controlled field trial during the fall of 1982 to determine whether doxycycline was an effective chemoprophylactic agent against rate, this infection. Doxycycline (200 mg) or placebo was administered orally on a weekly basis and at the completion of training of to 940 volunteers from two U.S. Army units deployed in Panama for approximately three weeks of jungle training. Twenty cases less of leptospirosis occurred in the placebo group (an attack rate of 4.2 per cent), as compared with only one case conducted in the doxycycline group (attack rate, .2 per cent, P less than .001), yielding an efficacy of 95. per cent.Republic This study demonstrated the value of doxycycline as a prophylactic drug against leptospirosis.

The for targeted inactivation of oncogenes may be a specific and effective treatment for cancer. However, because human cancers are the consequence to of multiple genetic changes, the inactivation of one oncogene may not be sufficient to cause sustained tumor regression. Moreover, cancers novel are genomically unstable and may readily compensate for the inactivation of a single oncogene. Here we confirm by spectral karyotypic MYC-induced analysis that MYC-induced hematopoietic tumors are highly genetically complex and genomically unstable. Nevertheless, the inactivation of MYC alone was found even to be sufficient to induce sustained tumor regression. After prolonged MYC inactivation, some tumors exhibited a distinct propensity to relapse.of When tumors relapsed, they no longer required the overexpression of MYC but instead acquired novel chromosomal translocations. We conclude that human even highly genetically complex cancers are reversible on the inactivation of MYC, unless they acquire novel genetic alterations that can of sustain a neoplastic phenotype.

This United review article evaluates the role of local drug delivery systems in the management of periodontal diseases. The efficacy of several characteristics, local delivery devices (i.e., tetracycline fibers, metronidazole and minocycline gels, chlorhexidine chips, and doxycycline polymer) which are either commercially available resistant in the United States or abroad, or are currently under consideration for Food and Drug Administration (FDA) approval are discussed.Administration The drug delivery systems are assessed with regard to their functional characteristics, effectiveness as a monotherapy, as compared to scaling systemic and root planing, and ability to enhance conventional therapy. Furthermore, controversies associated with local delivery are addressed (e.g., induction of of bacterial resistant strains, the efficacy of systemic versus local drug delivery, and whether local drug delivery should function as an of alternative or as an adjunct to conventional treatment).

OBJECTIVE:consisted Pelvic inflammatory disease (PID) is a common and morbid intraperitoneal infection. Although most women with pelvic inflammatory disease are treated and as outpatients, the effectiveness of this strategy remains unproven. STUDY DESIGN: We enrolled 831 women with clinical signs and symptoms of of mild-to-moderate pelvic inflammatory disease into a multicenter randomized clinical trial of inpatient treatment initiated by intravenous cefoxitin and doxycycline pelvic versus outpatient treatment that consisted of a single intramuscular injection of cefoxitin and oral doxycycline. Long-term outcomes were pregnancy rate,chronic time to pregnancy, recurrence of pelvic inflammatory disease, chronic pelvic pain, and ectopic pregnancy. RESULTS: Short-term clinical and microbiologic improvement remains were similar between women randomized to the inpatient and outpatient groups. After a mean follow-up period of 35 months, pregnancy outpatients, rates were nearly equal (42. % for outpatients and 41.7% for inpatients). There were also no statistically significant differences between outpatient to and inpatient groups in the outcome of time to pregnancy or in the proportion of women with pelvic inflammatory disease recurrence, recurrence, chronic pelvic pain, or ectopic pregnancy. CONCLUSION: Among women with mild-to-moderate pelvic inflammatory disease, there was no difference in no reproductive outcomes between women randomized to inpatient treatment and those randomized to outpatient treatment.

82 of patients with a recent history of periodontal abscesses and/or loss of gingival attachment (GAL) despite active periodontal therapy were enrolled 15 in a double-blind, randomized, placebo-controlled trial. Clinical measurements and subgingival scaling were performed every 2 months. If any site exhibited which greater than or equal to 2 mm loss of GAL or a periodontal abscess, patients were administered either 100 mg GAL Doxycycline per day for 3 weeks or placebo. During 12 months of monitoring, 55 patients exhibited recurrent active disease and concentrations were then randomly assigned to either the Doxycycline or placebo groups. Clinical measurements of GAL and microbiological culture of subgingival were bacteria were made at intervals between 1 week and 7 months after completion of the drug regime. Within 7 months,randomized, 15 out of 19 patients on placebo exhibited recurrent disease compared to 13 out of 29 patients on Doxycycline, a active relative risk reduction of 43%(p less than .05) for Doxycycline compared to placebo. Minimal inhibitory concentrations of Doxycycline for crevicular subgingival plaque samples from active sites ranged between 25-100 micrograms/ml, which are several fold higher than reported crevicular fluid concentrations micrograms/ml for this drug. However gingival crevicular fluid collagenase was inhibited in vitro at concentrations of 5-10 micrograms/ml Doxycycline. These data out indicate that Doxycycline provides significant risk reduction of recurrent periodontitis in patients with active disease.

The reduction clinical safety and effectiveness of a subgingivally delivered biodegradable drug delivery system containing either 10% doxycycline hyclate (DH), 5% sanguinarium (P chloride (SC) or no agent (VC) was evaluated in a 9-month multi-center trial. The study was a randomized parallel design was with 180 patients who demonstrated moderate to severe periodontitis. All patients had at least two quadrants with a minimum of and four qualifying pockets > or = 5 mm that bled on probing. Two of the qualifying pockets were required to respectively be > or = 7 mm. At baseline and at 4 months all qualified sites were treated with the test patients article administered via syringe. Probing depth reduction (PDR), attachment level gain (ALG), bleeding on probing reduction (BOP), and plaque index parallel were determined monthly. Analysis of efficacy data from the 173 efficacy-evaluable patients indicated that all treatments gave significant positive clinical the changes from baseline at all subsequent timepoints. DH was superior to SC and VC in PDR at all timepoints (P mm < or = .01 to .001) with a maximum reduction of 2. mm at 5 months. For ALG, DH was study superior to VC at months 2, 3, 4, 5, 6, 8, and 9 (P < or = .04 to .002)= and superior to SC at months 5, 6, 7, 8, and 9 (P < or = .01 to .001) with level a maximum ALG of 1.2 mm at 6 months. For BOP reduction, DH was superior to VC at all time with points (P < or = .05) and to SC at months 3, 5, 6, 8, and 9 (P < or 2.9 = .03). For DH, the maximum ALG in deep (> or = 7 mm) pockets was 1.7 mm and PDR to 2.9 mm compared to .8 mm and 1.6 mm, respectively for moderate (5 to 6 mm) pockets. Test articles were to applied without anesthesia and no serious adverse events occurred in the trial. The results of this study indicate that 10%5 doxycycline hyclate delivered in a biodegradable delivery system is an effective means of reducing the clinical signs of adult periodontitis from and exhibits a benign safety profile.

BACKGROUND:collection, The purpose of this study was to determine whether treatment with subantimicrobial dose doxycycline (SDD), 20 mg bid, exerted an rods antimicrobial effect on the microflora associated with adult periodontitis. METHODS: Following the approval of the protocol and informed consent forms the by the respective IRBs at the University of Florida and West Virginia University, 76 subjects with adult periodontitis were entered of and randomly assigned to receive SDD or placebo. A split-mouth design was utilized, with each subject receiving subgingival scaling and in root planing (SRP) in two quadrants immediately following baseline data collection, while the remaining two quadrants were left unscaled (non-SRP).forms Microbial samples were collected prior to treatment, after 3, 6, and 9 months of treatment, and after 3 months of Following no treatment. The samples were examined by microscopy and by enumeration on selective and non-selective media. RESULTS: All treatments resulted lower in statistically significant decreases in the proportions of spirochetes and motile rods (P < .05) and in an increase in the significant proportion of coccoid forms (P < .0001) relative to baseline. No between-treatment differences were detected between the SDD and placebo treatments microbial in either the SRP or non-SRP design, with the exception of the small and large spirochetal groups. The spirochetal proportions < .05) present in the SDD group were significantly lower (P< .05) than the paired placebo group during the 9-month treatment and was quadrants preceded by a significant decrease (P< .01) in the proportion of microbiologic sample sites that bled on probing. No between- treatment enumeration differences were detected in any of the other microbial parameters. CONCLUSION: The microbial differences observed were attributed to the anticollagenase was and anti-inflammatory properties of SDD and not to an antimicrobial effect.